Oncotarget Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity

(Impact Journals LLC) Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.Dr. Takeshi Isoyama from Daiichi Sankyo Co., Ltd. said, "FMS like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase expressed by acute myeloid leukemia (AML) cells in 70% to 90% of patients."